TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05608005

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panblok + MF59 Dose 1
Description: Pharmaceutical form: suspension for injection Route of administration: intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panblok + MF59 Dose 2
Description: Pharmaceutical form: suspension for injection Route of administration: intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Unadjuvanted Panblok Dose 3
Description: Pharmaceutical form: liquid for injection Route of administration: intramuscular
Study: NCT06429384

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Y-3 Injection/Y-3 blank injection
Description: The first dose should be completed as soon as possible after randomization; The time from the second dose to the first dose shall not be less than 12h, but not more than 24h+1h; The time interval of each subsequent administration is 24h±1h;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-3 Injection/Y-3 blank injection
Description: The first dose should be completed as soon as possible after randomization; The time from the second dose to the first dose shall not be less than 12h, but not more than 24h+1h; The time interval of each subsequent administration is 24h±1h;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-3 Injection/Y-3 blank injection
Description: The first dose should be completed as soon as possible after randomization; The time from the second dose to the first dose shall not be less than 12h, but not more than 24h+1h; The time interval of each subsequent administration is 24h±1h;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-3 Injection/Y-3 blank injection
Description: The first dose should be completed as soon as possible after randomization; The time from the second dose to the first dose shall not be less than 12h, but not more than 24h+1h; The time interval of each subsequent administration is 24h±1h;
Study: NCT06289322

Intervention type: OTHER
Group type: OTHER
Intervention: Digital toolkit for assessment
Description: The pilot study uses a digital assessment and intervention toolkit. The person with dementia and caregivers may choose from the digital interventions offered in the toolbox without any mandatory conditions.
Study: NCT04820283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care manager intervention (nurse)
Description: In this intervention, a primary care nurse provides the participant with self-management support to manage stress-related problems. The participant meets with the nurse face-to-face for typically 2 to 6 sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: In this intervention, the participant receives therapist supported self-help CBT. The participant randomized to this arm can choose to receive the treatment via an online treatment platform or via bibliotherapy, i.e., a self-help book.The treatment is comprised of 12 modules or chapters, which entail information about stress management techniques including behavioral activation and exposure. The participant that chooses online CBT is guided by a therapist who provides feedback on homework assignments through written asynchronous text messages; the patient who chooses bibliotherapy is guided by a therapist in typically 2 to 5 face-to-face sessions at a primary care clinic.
Study: NCT06302647

Intervention type: OTHER
Intervention: Questionnaires
Description: Three questionnaires have been developed to be used by subjects, pharmaceutical industry or doctors in regards to the willingness to use a platform for clinical trial recruitment

Intervention type: OTHER
Intervention: Questionnaires
Description: Three questionnaires have been developed to be used by subjects, pharmaceutical industry or doctors in regards to the willingness to use a platform for clinical trial recruitment

Intervention type: OTHER
Intervention: Questionnaires
Description: Three questionnaires have been developed to be used by subjects, pharmaceutical industry or doctors in regards to the willingness to use a platform for clinical trial recruitment
Study: NCT02675842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Smoked Cannabis High CBD/low THC
Description: Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes (15.76% CBD; 3.11% -9-THC) over the course of 2-3 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Smoked Placebo Cannabis Low CBD/low THC
Description: Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes Cannabis (0.0% CBD/ 0.01% -9-THC) over the course of 2-3 hours.
Study: NCT05038462

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin and DHA
Description: The intervention consists in the maternal oral administration of 1000mg of Lactoferrin and 1000mg of DHA daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Product with the same physical appearance and taste as the main intervention but without therapeutic effect
Study: NCT05424172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage-I, Group 1: Self monitoring using Non-interactive App
Description: Participants in Group 1 will have minimal features that affect compliance (notifications, rewards, EMA, etc.) and no modifications to their exercise program after initial prescription.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage-I, Group 2: Self monitoring using Interactive App
Description: Participants in Group 2 will use the version of the exercise app that has been modified based on the findings from Phases 1 and 2 of this study. Group 2 will be able to use the full features of the interactive app including notifications, ability to submit videos, and non-synchronous messaging/communicating with the researcher. Additionally, participants in Group 2 will be asked to complete 2-5 EMA-based surveys daily to gain information about the participant's barriers and facilitators to exercise. The information from the EMA questionnaires will be used to progress and modify the exercise program at regular intervals for each participant in Group 2.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage-II, Groups 1a/2a: E-Coaching 2x per month
Description: In addition to the Stage-I assigned app, participants will be asked to complete at least daily EMA questionnaires and e-coaching sessions two times a month throughout Stage-II (weeks 13-24). Participants will only receive the augmented e-coaching intervention if they were not adherent to the exercise guidelines for at least 50% of the weeks during Stage-I (weeks 1-12).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage-II, Groups 1b/2b: E-Coaching 4x per month
Description: In addition to the Stage-I assigned app, participants will be asked to complete at least daily EMA questionnaires and e-coaching sessions four times a month throughout Stage-II (weeks 13-24). Participants will only receive the augmented e-coaching intervention if they were not adherent to the exercise guidelines for at least 50% of the weeks during Stage-I (weeks 1-12).
Study: NCT05542550

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voice Rest
Description: Voice rest restricting patient phonation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Voice Rest
Description: No Voice rest
Study: NCT03553914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLM60
Description: PLM60 will be administered via intravenous infusion in 28-day cycles for up to 7 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLM60
Description: PLM60 will be administered via intravenous infusion in 28-day cycles for up to 7 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLM60
Description: PLM60 will be administered via intravenous infusion in 28-day cycles for up to 7 cycles.
Study: NCT05687747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabelled tracer, 68Gallium-FAPI-46 PET/MRI
Description: 68Gallium-FAPI-46 PET/MRI is a novel radioactive diagnostic tracer used with Positron Emission Tomography imaging. It defects Fibroblast Activation Protein positive cancer cells and cancer associated fibroblasts.
Study: NCT04582149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeControl Eye-tracking Device
Description: The EyeControl is a new, wearable, eye-tracking device that facilitates communication by means of internal feedback to the patients with a bone-conducting speaker. In this way, the device can ask the patient what he or she wants to say, and the patient replies by eye gestures such as blinking or moving the eyes in a certain direction. Once the patient is able to operate the device, it will stay on the patient for as long as she or he would like it on, or until the patient is successfully extubated or discharged from the ICU, whichever is earliest.
Study: NCT05291442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: To integrate Family System Care and Theme Care Action Module
Description: First, understand the care needs of patients and caregivers, and apply The Specific Thematic Nursing Care Action Modules (STNC-AM) platform for education and training.~The Specific Thematic Nursing Care Action Modules (STNC-AM) platform that we present here is an educational program that integrates education and coaching. STNC-AM has six key aspects: stroke prevention, management of emotions, management of fatigue, physical activity, caregiver training, and integrative resources. Each scope contains detailed care guidance.
Study: NCT06466785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efepoetin Alfa
Description: Efepoetin alfa (Epoetin-Fc fusion protein, GX-E2 or GX-E4,) is a novel long-acting erythropoietin-hybrid fragment crystallizable (Fc) fusion protein developed by Genexine, intended for treatment and maintenance of anemia due to CKD with or without dialysis. Its drug substance is a recombinant form of human EPO and hybrid Fc (hyFc®) fragment consisting of 2 subunits with a total of 411 amino acid residues. Each subunit contains an EPO molecule linked to a hybrid Fc fragment of c terminal of CH2 and CH3 regions from IgG4 and to N-terminal of CH2 region and the hinge sequence from IgD. These 2 subunits are joined by a single disulfide bond at the hinge region of each subunit. Half-life is 138.5-157.9 hours. It is an acidic glycoprotein of about 30 kDa and comprises 165 amino acids and 4 glycans. Circulating EPO exhibits several glycosylation isoforms that differ in electrical charge and biological activity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin Alfa
Description: Darbepoetin alfa is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy
Study: NCT05962047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Games of WonderTree Augmented Reality
Description: Participants of group 1 (experimental group) will augmented reality based interventions comprising of games of Wonder Tree

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional therapy
Description: Traditional therapy based on play activities utilizing blocks, colors, Velcro-based toys.
Study: NCT06396585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 ,Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Participants will receive anlotinib,12mg, qd，d1-d14，Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive Oxaliplatin, 130mg/m2, iv, day 1 ,Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur
Description: Participants will receive S-1 40-60mg/m2/c次，bid ，d1-d14，Q3W
Study: NCT04434599

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopically guided ablation
Description: Catheter ablation of the cavotricuspid isthmus using ablation catheters guided by fluoroscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact force guided ablation
Description: Catheter ablation of the cavotricuspid isthmus using ablation catheters guided by contact force measurement and 3D electroanatomic mapping

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Local impedance guide ablation
Description: Catheter ablation of the cavotricuspid isthmus using ablation catheters guided by local impedance measurement and ultra-high density 3D electroanatomic mapping
Study: NCT05476042

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prescription of placebo
Description: Normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin prescription
Description: Erythropoietin 3000 units in normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin prescription
Description: Erythropoietin 6000 units in normal saline
Study: NCT06155500

Intervention type: OTHER
Intervention: OTQ923
Description: There is no treatment allocation. Patients administered were OTQ923 while enrolled on the treatment protocol CADPT03A12101 (NCT04443907)
Study: NCT06010498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eye mask
Description: * First day morning The Introductory Characteristics Form will be filled.~* First day night Standard care will be given~* Second day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled~* Second day night Standard care will be given + eye patch will be applied (22:00-06:00)~* Third day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled~* Third day night Standard care will be given + eye patch will be applied (22:00-06:00)~* Fourth day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standart care
Description: Control group (n)~* First day morning The Introductory Characteristics Form will be filled.~* First day night Standard care will be given~* Second day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled~* Second day night Standard care will be given~* Third day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled~* Third day night Standard care will be given)~* Fourth day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled
Study: NCT05328726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR-18
Description: As previously described in Arms

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be dosed in an identical manner to active study drug.
Study: NCT05435170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linerixibat
Description: linerixibat will be administered per the treatment sequence
Study: NCT04982263

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood coagulation profile
Description: Venous blood sample for measurement of blood coagulation profile
Study: NCT06323603

Intervention type: OTHER
Intervention: Micro and nanoplastic
Description: Biological samples will be obtained to evaluate the different biomarkers selected

Intervention type: OTHER
Intervention: Micro and nanoplastic
Description: Biological samples will be obtained to evaluate the different biomarkers selected
Study: NCT05449197

Intervention type: OTHER
Intervention: HEMOPHAR e-learning program
Description: training on professional practice by following HEMOPHAR e-learning program
Study: NCT06043115

Intervention type: OTHER
Intervention: covid-19 survival cohort
Description: consists of surviving patients

Intervention type: OTHER
Intervention: covid-19 mortality cohort
Description: consists of deceased patients
Study: NCT05492734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDG-5506
Description: single oral dose
Study: NCT05577286

Intervention type: OTHER
Group type: OTHER
Intervention: regular care
Description: the regular medical treatment without change of their daily activity routine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: regular care
Description: the regular medical treatment without change of their daily activity routine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plyometric training
Description: designed plyometric training program for 30 minutes, three times a week for two successive months
Study: NCT04946396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine intravenous infusion
Description: Dexmedetomidine intravenous infusion during laparoscopic cholecystecthomy

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0.9%sodium chloride
Description: 0.9%sodium chloride intravenous infusion during laparoscopic cholecystecthomy
Study: NCT05444842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: insulin iontophoresis
Description: All wounds will be thoroughly cleansed with physiologic serum before the therapeutic treatment began (i.e., saline 0.9 percent). after cleaning the wound the insulin ions and oleic acid will be injected into the electrode of iontophoresis device (Phoresor_ IIAuto, ModelPM850, IOMED) then The device was set to the required dose of 40 mA-min, and the current intensity was gradually increased based on the subject's tolerance (ranging from 1 to 4 mA). The device computed the required time for the selected dose automatically.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: topical insulin
Description: All wounds will be thoroughly cleansed with physiologic serum before the therapeutic treatment began (i.e., saline 0.9 percent) after cleaning the wound For each 10cm2 of the wound, patients will get ten units (0.1 mL) of insulin crystal in solution with 1mL saline (0.9 percent). An insulin syringe needle was used to spray the solution twice daily on the wound area.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: All wounds will be thoroughly cleansed with physiologic serum before the therapeutic treatment began (i.e., saline 0.9 percent) after cleaning the wound For each 10cm2 of wound 1mL 0.9 percent saline was given.
Study: NCT04925167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban
Description: Argatroban continuous intravenous injection maintained APTT at 1.5 times of baseline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: unfractionated heparin
Description: unfractionated heparin continuous intravenous injection maintained APTT at 1.5 times of baseline.
Study: NCT05075837

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Virus -specific T cells
Description: The product is obtained by leukapheresis of a family donor responsive to the virus: consists of virus- specific T lymphocytes (both CD4+ and CD8+) resuspended in PBS / EDTA buffer plus 0.5% Albumin Human. The productive process lasts two consecutive days and includes two phases: a brief activation with specific viral peptide followed by immunomagnetic separation using the CliniMACS® CCS (IFNγ) capture system which allows a fast and automated separation of IFNγ secreting lymphocytes
Study: NCT04942652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg
Description: Itraconazole 100 mg capsule x 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg
Description: Itraconazole 100 mg capsule x 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg
Description: Itraconazole 100 mg capsule x 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Description: Esomeprazole 40 mg tablet x 1
Study: NCT05336916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Buddy
Description: Mindfulness-based Cognitive Behavioural Therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Buddy
Description: Mindfulness-based Cognitive Behavioural Therapy
Study: NCT06037902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: patients undergo simulation twice, with and without CPAP
Study: NCT04745013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRIORITY
Description: PeRsonalIzed remOtely guided preventive exeRcIse therapy for a healThY heart

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Only a written personalized exercise prescription will be provided.
Study: NCT06033885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PONDUS®
Description: PONDUS® is a CE-marked medical device to support the positioning of the user in a R82 standing frame.~PONDUS® is designed as a pair of instrumented foot plates and an app as an external display.~PONDUS® gives individual readings from the right and the left plate telling how much force is applied to each plate by combining high frequency data from three pressure sensors in each plate. The data is displayed in the app as a time series graph and can also be exported.
Study: NCT04924712

Intervention type: OTHER
Intervention: Measurement of blood immune populations and microbiota distribution.
Description: Measurement of peripheral cell populations by spectral cytometry and in parallel, sequencing of intestinal and urinary bacterial 16S RNA of each patient.

Intervention type: OTHER
Intervention: Measurement of blood immune populations and microbiota distribution.
Description: Measurement of peripheral cell populations by spectral cytometry and in parallel, sequencing of intestinal and urinary bacterial 16S RNA of each patient.
Study: NCT04841824

Intervention type: OTHER
Intervention: Observational study
Description: Observational study. Groups are defined based on baseline patients' characteristics : presence or absence of sepsis.
Study: NCT05080699

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peptamen Intense VHP, Nestlé Health Science, Switzerland
Description: An enteral formula containing hydrolyzed whey protein, maltodextrin, long-chain triglycerides, medium chain triglycerides (MCT), vitamins and minerals. Compared to standard enteral formula, Peptamen Intense is higher in protein (37 kcal%) and lower in carbohydrates (29 kcal%). The energy content is 1.0 kcal/mL.